Deucravacitinib

Psoriasis is an immune-mediated chronic, systemic, inflammatory disease, and its core pathogenesis is regulated by the JAK-STAT pathway mediated by the Janus kinase (JAK) family.

1. Drug name

1. Generic name: Deucravacitinib;

2. Trade name: SOTYKTU™.

2. Indications

Deuterated colexitinib is suitable for the treatment of moderate to severe plaque psoriasis in adults and is suitable for patients receiving systemic therapy or phototherapy.

3. Specifications and properties

1. Specifications: 6mg

2. Properties: Tablets

4. Main ingredients < /h2>

Active ingredient:Deuterated colexitinib

5. Usage and dosage

1. Recommended dosage: 6 mg orally, once a day, before or after a meal.

2. How to take the medicine: Swallow the tablet whole. Do not crush, cut or chew.

3. Treatment of missed doses: If you remember to take a missed dose on the same day, you can take it again at the original time the next day.

4. Treatment of vomiting: If you vomit after taking the medicine, there is no need to retake it.

VI. Dose adjustment

1. Hepatic insufficiency : Contraindicated in patients with severe liver damage (Child-Pugh C grade); no dose adjustment is required for mild to moderate liver damage.

2. Infection or laboratory abnormality : If severe infection occurs, liver enzymes increase ≥3 times ULN or creatine kinase (CPK) significantly increases, the drug needs to be suspended or discontinued.

7. Medication precautions

1. Risk of infection : Screening for tuberculosis (TB) and hepatitis B/C is required before treatment, and avoid use in patients with active infections.

2. Vaccination : Avoid the use of live vaccines and complete recommended immunizations before treatment.

3. Monitoring requirements : Regularly check liver function, blood lipids (especially triglycerides) and blood routine.

4. Muscle symptoms : If you have unexplained muscle pain or weakness accompanied by fever, you need to seek medical attention immediately.

8. Medication for special groups

1. U200c for pregnant women: It is prohibited. Animal tests show that high doses are not teratogenic, but there is insufficient human data.

2. Lactation : Suspend medication or stop breastfeeding.

3. Elderly patients : Patients aged ≥65 years old have an increased risk of serious adverse reactions (such as infection).

4. Hepatic and renal insufficiency : Contraindicated for severe liver damage; no dose adjustment is required for renal insufficiency.

9. Adverse reactions

1. Common (≥1%) : Upper respiratory tract infection (19.2%), elevated CPK (2.7%), oral herpes (2.0%), oral ulcer (1.9%), folliculitis (1.7%), acne (1.4%).

2. Severe reactions : Infection (pneumonia, COVID-19), malignant tumor (lymphoma), hepatotoxicity, rhabdomyolysis.

10. Contraindications

It is prohibited for those allergic to deuterated coxitinib or any excipients.

11. Drug interactions

1. Strong CYP3A4 inducer/inhibitor : Avoid combined use (such as rifampicin, ketoconazole).

2. Live vaccine : The vaccination interval needs to be cautious.

12. Storage method

1. Storage temperature: 20-25°C (short-term 15-30°C allowed).

2. Keep the original packaging and avoid moisture and light.